Art. -Nr.: HY-N0003

Honokiol

(Synonyms: NSC 293100)

69 Cited Publications

Kundenbewertung

Based on 69 publication(s) in Google Scholar

Honokiol is a bioactive, biphenolic phytochemical that possesses potent antioxidative, anti-inflammatory, antiangiogenic, and anticancer activities by targeting a variety of signaling molecules. It inhibits the activation of Akt. Honokiol can readily cross the blood brain barrier.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 99.85%
CAS. Nr.: 35354-74-6
Formel: C₁₈H₁₈O₂
Molecular Weight:266.33

Speicherung:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 1 year , -20°C, 6 months

Honokiol Chemical Structure

CAS. Nr.: 35354-74-6

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
- Clinical Trial
Chemical Information
Publications (69)
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Protokoll
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

IC₅₀ & Target^[4]

ERK1

ERK2

Autophagy

Alle Akt Isoform-spezifische Produkte anzeigen :

Alle ERK Isoform-spezifische Produkte anzeigen :

Cellular Effect

Cell Line	Type	Value	Description	References
A2780	IC₅₀	30.5 μM Compound: 1	Antiproliferative activity against cisplatin-sensitive human A2780 cells by MTT assay Antiproliferative activity against cisplatin-sensitive human A2780 cells by MTT assay	[PMID: 19589678]
A2780	IC₅₀	30.5 μM Compound: Honokiol	Antiproliferative activity against human A2780 cells after 24 hrs by MTT assay Antiproliferative activity against human A2780 cells after 24 hrs by MTT assay	[PMID: 31278004]
A2780	IC₅₀	31.58 μM Compound: HN; 2a	Antiproliferative activity against human A2780 cells assessed as reduction in cell viability after 48 hrs by MTT assay Antiproliferative activity against human A2780 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 32996316]
A2780	IC₅₀	41.2 μM Compound: 1	Antiproliferative activity against cisplatin-resistant human A2780 cells by MTT assay Antiproliferative activity against cisplatin-resistant human A2780 cells by MTT assay	[PMID: 19589678]
A549	IC₅₀	>5 μg/mL Compound: 6	Cytotoxicity against human A549 cells by MTT assay Cytotoxicity against human A549 cells by MTT assay	[PMID: 17918910]
A549	IC₅₀	12.51 μM Compound: Honokiol	Cytotoxicity against human A549 cells after 24 hrs by MTS assay Cytotoxicity against human A549 cells after 24 hrs by MTS assay	[PMID: 22533983]
A549	IC₅₀	29.7 μM Compound: Honokiol	Antiproliferative activity against human A549 cells by MTT assay Antiproliferative activity against human A549 cells by MTT assay	[PMID: 31278004]
A549	IC₅₀	34.1 μM Compound: Honokiol	Antiproliferative activity against human A549 cells after 24 hrs by MTT assay Antiproliferative activity against human A549 cells after 24 hrs by MTT assay	[PMID: 31278004]
A549	IC₅₀	35 μM Compound: 1	Antiproliferative activity against human A549 cells by MTT assay Antiproliferative activity against human A549 cells by MTT assay	[PMID: 19589678]
A549	IC₅₀	35 μM Compound: Honokiol	Antiproliferative activity against human A549 cells after 24 hrs by MTT assay Antiproliferative activity against human A549 cells after 24 hrs by MTT assay	[PMID: 21853991]
A549	IC₅₀	35.31 μM Compound: 1; HK	Antiproliferative activity against human A549 cells after 72 hrs by MTT assay Antiproliferative activity against human A549 cells after 72 hrs by MTT assay	[PMID: 30006164]
A549	IC₅₀	35.41 μM Compound: Honokiol	Antiproliferative activity against human A549 cells after 48 hrs by MTT assay Antiproliferative activity against human A549 cells after 48 hrs by MTT assay	[PMID: 31278004]
A549	IC₅₀	38.04 μM Compound: HN; 2a	Antiproliferative activity against human A549 cells assessed as reduction in cell viability after 48 hrs by MTT assay Antiproliferative activity against human A549 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 32996316]
A549	IC₅₀	48.14 μM Compound: HN	Antiproliferative activity against human A549 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Antiproliferative activity against human A549 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 38086195]
A549	IC₅₀	7.75 μM Compound: Honokiol	Cytotoxicity against human A549 cells after 72 hrs by MTS assay Cytotoxicity against human A549 cells after 72 hrs by MTS assay	[PMID: 22533983]
BV-2	IC₅₀	17 μM Compound: 1	Anti-inflammatory activity in mouse BV2 cells assessed as inhibition of LPS-induced nitric oxide production after 24 hrs by griess assay Anti-inflammatory activity in mouse BV2 cells assessed as inhibition of LPS-induced nitric oxide production after 24 hrs by griess assay	[PMID: 30472026]
CCRF-CEM	CC₅₀	10.9 μM Compound: 1, honokiol	Cytotoxicity against human CEM cells Cytotoxicity against human CEM cells	[PMID: 16722664]
CCRF-CEM	IC₅₀	10.9 μM Compound: 2	Cytotoxicity against human CEM cells Cytotoxicity against human CEM cells	[PMID: 17587572]
CHO	EC₅₀	>10 μM Compound: 1	Agonist activity at recombinant human CB1 receptor expressed in CHO cells assessed as inhibition of forskolin-induced cAMP accumulation after 5 mins by cAMP-competition binding assay Agonist activity at recombinant human CB1 receptor expressed in CHO cells assessed as inhibition of forskolin-induced cAMP accumulation after 5 mins by cAMP-competition binding assay	[PMID: 24900561]
CNE2Z	IC₅₀	31.27 μM Compound: Honokiol	Antiproliferative activity against human CNE2Z cells assessed as growth inhibition after 72 hrs by MTT assay Antiproliferative activity against human CNE2Z cells assessed as growth inhibition after 72 hrs by MTT assay	[PMID: 31831382]
HCC827	IC₅₀	33.88 μM Compound: 1; HK	Antiproliferative activity against human HCC827 cells after 72 hrs by MTT assay Antiproliferative activity against human HCC827 cells after 72 hrs by MTT assay	[PMID: 30006164]
HCT-116	IC₅₀	17.25 μM Compound: Honokiol	Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay	[PMID: 38759254]
HCT-116	IC₅₀	19.05 μM Compound: Honokiol	Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay	[PMID: 31278004]
HCT-116	IC₅₀	47.65 μM Compound: 35	Antitumor activity against human HCT-116 cells assessed as reduction in cell viability incubated for 48 hrs by CCK8 assay Antitumor activity against human HCT-116 cells assessed as reduction in cell viability incubated for 48 hrs by CCK8 assay	[PMID: 36332549]
HEK293	EC₅₀	11.8 μM Compound: 1	Agonist activity at RXRalpha in HEK293 cells assessed as transcriptional activation after 48 hrs by luciferase reporter gene assay Agonist activity at RXRalpha in HEK293 cells assessed as transcriptional activation after 48 hrs by luciferase reporter gene assay	[PMID: 20695472]
HEK293	ED₅₀	11.8 μM Compound: Honokiol	Agonist activity at human RXR-alpha expressed in HEK293 cells coexpressing with pCMX-beta-gal after 24 to 48 hrs by luciferase reporter gene assay Agonist activity at human RXR-alpha expressed in HEK293 cells coexpressing with pCMX-beta-gal after 24 to 48 hrs by luciferase reporter gene assay	[PMID: 24959987]
HEK293	IC₅₀	40 μM Compound: Ho	Cytotoxicity against HEK293 cells assessed as decrease in cell viability after 2 days by MTT assay Cytotoxicity against HEK293 cells assessed as decrease in cell viability after 2 days by MTT assay	[PMID: 30733086]
HEK293	IC₅₀	9.3 μg/mL Compound: Honokiol	Cytotoxicity against HEK293 cells assessed as reduction in cell growth after 3 days by MTT assay Cytotoxicity against HEK293 cells assessed as reduction in cell growth after 3 days by MTT assay	[PMID: 27259399]
HeLa	IC₅₀	>5 μg/mL Compound: 6	Cytotoxicity against human HeLa cells by MTT assay Cytotoxicity against human HeLa cells by MTT assay	[PMID: 17918910]
HeLa	IC₅₀	62 μM Compound: Honokiol	Antiproliferative activity against human HeLa cells Antiproliferative activity against human HeLa cells	[PMID: 31278004]
HepG2	IC₅₀	16.5 μM Compound: Honokiol	Antiproliferative activity against human HepG2 cells after 24 hrs by MTT assay Antiproliferative activity against human HepG2 cells after 24 hrs by MTT assay	[PMID: 21853991]
HepG2	IC₅₀	16.5 μM Compound: 2	Cytotoxicity of compound against human liver tumor cell line (Hep-G2) was determined Cytotoxicity of compound against human liver tumor cell line (Hep-G2) was determined	[PMID: 15582432]
HepG2	IC₅₀	23.85 μM Compound: HN; 2a	Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability after 48 hrs by MTT assay Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 32996316]
HepG2	IC₅₀	32.9 μM Compound: Honokiol	Antiproliferative activity against human HepG2 cells after 24 hrs by MTT assay Antiproliferative activity against human HepG2 cells after 24 hrs by MTT assay	[PMID: 31278004]
HepG2	IC₅₀	33.88 μM Compound: Honokiol	Antiproliferative activity against human HepG2 cells after 72 hrs by MTT assay Antiproliferative activity against human HepG2 cells after 72 hrs by MTT assay	[PMID: 31278004]
HepG2	IC₅₀	34.3 μM Compound: Honokiol	Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay	[PMID: 31278004]
HepG2	IC₅₀	41.42 μM Compound: HN	Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 38086195]
HT-29	IC₅₀	13.24 μM Compound: Honokiol	Cytotoxicity against human HT-29 cells after 72 hrs by MTS assay Cytotoxicity against human HT-29 cells after 72 hrs by MTS assay	[PMID: 22533983]
HT-29	IC₅₀	23.05 μM Compound: Honokiol	Cytotoxicity against human HT-29 cells after 24 hrs by MTS assay Cytotoxicity against human HT-29 cells after 24 hrs by MTS assay	[PMID: 22533983]
HT-29	IC₅₀	25 μM Compound: Ho	Cytotoxicity against human HT-29 cells assessed as decrease in cell viability after 2 days by MTT assay Cytotoxicity against human HT-29 cells assessed as decrease in cell viability after 2 days by MTT assay	[PMID: 30733086]
HT-29	IC₅₀	31.58 μM Compound: HN; 2a	Antiproliferative activity against human HT29 cells assessed as reduction in cell viability after 48 hrs by MTT assay Antiproliferative activity against human HT29 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 32996316]
HT-29	IC₅₀	6.1 μg/mL Compound: Honokiol	Cytotoxicity against human HT-29 cells assessed as reduction in cell growth after 3 days by MTT assay Cytotoxicity against human HT-29 cells assessed as reduction in cell growth after 3 days by MTT assay	[PMID: 27259399]
Huh-7	EC₅₀	9.4 μM Compound: Honokiol	Antiviral activity against HCV infected in human Huh7.5 cells Antiviral activity against HCV infected in human Huh7.5 cells	[PMID: 24388689]
Huh-7	IC₅₀	58.5 μM Compound: Honokiol	Cytotoxicity against human Huh7.5 cells after 72 hrs Cytotoxicity against human Huh7.5 cells after 72 hrs	[PMID: 24400834]
Huh-7	IC₅₀	58.5 μM Compound: Honokiol	Cytotoxicity against human Huh7.5 cells Cytotoxicity against human Huh7.5 cells	[PMID: 24388689]
HUVEC	IC₅₀	52.6 μM Compound: Honokiol	Antiproliferative activity against human HUVEC cells after 24 hrs by MTT assay Antiproliferative activity against human HUVEC cells after 24 hrs by MTT assay	[PMID: 21853991]
I10	IC₅₀	31.11 μM Compound: Honokiol	Antiproliferative activity against mouse I10 cells assessed as growth inhibition after 72 hrs by MTT assay Antiproliferative activity against mouse I10 cells assessed as growth inhibition after 72 hrs by MTT assay	[PMID: 31831382]
K562	IC₅₀	>5 μg/mL Compound: 6	Cytotoxicity against human K562 cells by MTT assay Cytotoxicity against human K562 cells by MTT assay	[PMID: 17918910]
K562	IC₅₀	21.1 μM Compound: 1	Antiproliferative activity against human K562 cells by MTT assay Antiproliferative activity against human K562 cells by MTT assay	[PMID: 19589678]
K562	IC₅₀	22.1 μM Compound: Honokiol	Antiproliferative activity against human K562 cells after 24 hrs by MTT assay Antiproliferative activity against human K562 cells after 24 hrs by MTT assay	[PMID: 31278004]
K562	IC₅₀	23.91 μM Compound: Honokiol	Antiproliferative activity against human K562 cells after 48 hrs by MTT assay Antiproliferative activity against human K562 cells after 48 hrs by MTT assay	[PMID: 31278004]
K562	IC₅₀	28.4 μM Compound: Honokiol	Antiproliferative activity against human K562 cells by MTT assay Antiproliferative activity against human K562 cells by MTT assay	[PMID: 31278004]
KYSE-450	IC₅₀	32.41 μM Compound: Honokiol	Antiproliferative activity against human KYSE-450 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay Antiproliferative activity against human KYSE-450 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay	[PMID: 38759254]
L02	IC₅₀	25.49 μM Compound: HN; 2a	Antiproliferative activity against human L02 cells assessed as reduction in cell viability after 48 hrs by MTT assay Antiproliferative activity against human L02 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 32996316]
L02	IC₅₀	47.93 μM Compound: HN	Cytotoxicity against human HL7702 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity against human HL7702 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 38086195]
Lewis lung carcinoma cell line	IC₅₀	65.4 μM Compound: Honokiol	Antiproliferative activity against mouse LL/2 cells after 24 hrs by MTT assay Antiproliferative activity against mouse LL/2 cells after 24 hrs by MTT assay	[PMID: 21853991]
MCF7	IC₅₀	35 μM Compound: Ho	Cytotoxicity against human MCF7 cells assessed as decrease in cell viability after 2 days by MTT assay Cytotoxicity against human MCF7 cells assessed as decrease in cell viability after 2 days by MTT assay	[PMID: 30733086]
MCF7	IC₅₀	41.8 μM Compound: Honokiol	Antiproliferative activity against human MCF7 cells assessed as growth inhibition after 72 hrs by MTT assay Antiproliferative activity against human MCF7 cells assessed as growth inhibition after 72 hrs by MTT assay	[PMID: 31831382]
MCF7	IC₅₀	5 μg/mL Compound: Honokiol	Cytotoxicity against human MCF7 cells assessed as reduction in cell growth after 3 days by MTT assay Cytotoxicity against human MCF7 cells assessed as reduction in cell growth after 3 days by MTT assay	[PMID: 27259399]
MDA-MB-231	IC₅₀	44.89 μM Compound: Honokiol	Antiproliferative activity against human MDA-MB-231 cells measured after 24 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells measured after 24 hrs by MTT assay	[PMID: 34605238]
MGC-803	IC₅₀	11.77 μM Compound: Honokiol	Antiproliferative activity against human MGC-803 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay Antiproliferative activity against human MGC-803 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay	[PMID: 38759254]
NCI-H1650	IC₅₀	37.35 μM Compound: 1; HK	Antiproliferative activity against human NCI-H1650 cells after 72 hrs by MTT assay Antiproliferative activity against human NCI-H1650 cells after 72 hrs by MTT assay	[PMID: 30006164]
NCI-H1975	IC₅₀	30.2 μM Compound: 1; HK	Antiproliferative activity against human NCI-H1975 cells after 72 hrs by MTT assay Antiproliferative activity against human NCI-H1975 cells after 72 hrs by MTT assay	[PMID: 30006164]
NCI-H1975	IC₅₀	30.2 μM Compound: Honokiol	Antiproliferative activity against human NCI-H1975 cells after 72 hrs by MTT assay Antiproliferative activity against human NCI-H1975 cells after 72 hrs by MTT assay	[PMID: 31278004]
NCI-H358	IC₅₀	31.57 μM Compound: 1; HK	Antiproliferative activity against human NCI-H358 cells after 72 hrs by MTT assay Antiproliferative activity against human NCI-H358 cells after 72 hrs by MTT assay	[PMID: 30006164]
NCI-H441	IC₅₀	33.32 μM Compound: 1; HK	Antiproliferative activity against human H441 cells after 72 hrs by MTT assay Antiproliferative activity against human H441 cells after 72 hrs by MTT assay	[PMID: 30006164]
NCI-H446	IC₅₀	44.49 μM Compound: HN	Antiproliferative activity against human NCI-H446 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Antiproliferative activity against human NCI-H446 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 38086195]
NCI-H460	IC₅₀	38.46 μM Compound: 1; HK	Antiproliferative activity against human H460 cells after 72 hrs by MTT assay Antiproliferative activity against human H460 cells after 72 hrs by MTT assay	[PMID: 30006164]
Oocyte	EC₅₀	23.4 μM Compound: Hon, HK	Modulation of GABA Aalpha5beta2 receptor expressed in Xenopus laevis oocytes assessed as potentiation of GABA-induced chloride current at holding potential -70 mV by two-microelectrode voltage clamp technique Modulation of GABA Aalpha5beta2 receptor expressed in Xenopus laevis oocytes assessed as potentiation of GABA-induced chloride current at holding potential -70 mV by two-microelectrode voltage clamp technique	[PMID: 21699169]
Oocyte	EC₅₀	36.2 μM Compound: Hon, HK	Modulation of GABA alpha1beta2gamma2s receptor expressed in Xenopus laevis oocytes assessed as potentiation of GABA-induced chloride current at holding potential -70 mV by two-microelectrode voltage clamp technique Modulation of GABA alpha1beta2gamma2s receptor expressed in Xenopus laevis oocytes assessed as potentiation of GABA-induced chloride current at holding potential -70 mV by two-microelectrode voltage clamp technique	[PMID: 21699169]
Oocyte	EC₅₀	39.3 μM Compound: Hon, HK	Modulation of GABA Aalpha1beta2 receptor expressed in Xenopus laevis oocytes assessed as potentiation of GABA-induced chloride current at holding potential -70 mV by two-microelectrode voltage clamp technique Modulation of GABA Aalpha1beta2 receptor expressed in Xenopus laevis oocytes assessed as potentiation of GABA-induced chloride current at holding potential -70 mV by two-microelectrode voltage clamp technique	[PMID: 21699169]
Oocyte	EC₅₀	46.4 μM Compound: Hon, HK	Modulation of GABA Aalpha2beta2 receptor expressed in Xenopus laevis oocytes assessed as potentiation of GABA-induced chloride current at holding potential -70 mV by two-microelectrode voltage clamp technique Modulation of GABA Aalpha2beta2 receptor expressed in Xenopus laevis oocytes assessed as potentiation of GABA-induced chloride current at holding potential -70 mV by two-microelectrode voltage clamp technique	[PMID: 21699169]
Oocyte	EC₅₀	52.4 μM Compound: Hon, HK	Modulation of GABA Aalpha3beta2 receptor expressed in Xenopus laevis oocytes assessed as potentiation of GABA-induced chloride current at holding potential -70 mV by two-microelectrode voltage clamp technique Modulation of GABA Aalpha3beta2 receptor expressed in Xenopus laevis oocytes assessed as potentiation of GABA-induced chloride current at holding potential -70 mV by two-microelectrode voltage clamp technique	[PMID: 21699169]
Oocyte	EC₅₀	57 μM Compound: Hon, HK	Modulation of GABA Aalpha1beta1 receptor expressed in Xenopus laevis oocytes assessed as potentiation of GABA-induced chloride current at holding potential -70 mV by two-microelectrode voltage clamp technique Modulation of GABA Aalpha1beta1 receptor expressed in Xenopus laevis oocytes assessed as potentiation of GABA-induced chloride current at holding potential -70 mV by two-microelectrode voltage clamp technique	[PMID: 21699169]
Oocyte	EC₅₀	59.6 μM Compound: Hon, HK	Modulation of GABA Aalpha1beta3 receptor expressed in Xenopus laevis oocytes assessed as potentiation of GABA-induced chloride current at holding potential -70 mV by two-microelectrode voltage clamp technique Modulation of GABA Aalpha1beta3 receptor expressed in Xenopus laevis oocytes assessed as potentiation of GABA-induced chloride current at holding potential -70 mV by two-microelectrode voltage clamp technique	[PMID: 21699169]
PANC-1	IC₅₀	31.24 μM Compound: HN; 2a	Antiproliferative activity against human PANC1 cells assessed as reduction in cell viability after 48 hrs by MTT assay Antiproliferative activity against human PANC1 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 32996316]
PBMC	CC₅₀	16.1 μM Compound: 1, honokiol	Cytotoxicity against human PBM cells Cytotoxicity against human PBM cells	[PMID: 16722664]
PC-3	IC₅₀	29.03 μM Compound: HN; 2a	Antiproliferative activity against human PC-3 cells assessed as reduction in cell viability after 48 hrs by MTT assay Antiproliferative activity against human PC-3 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 32996316]
PC-9	IC₅₀	36.72 μM Compound: 1; HK	Antiproliferative activity against human PC9 cells after 72 hrs by MTT assay Antiproliferative activity against human PC9 cells after 72 hrs by MTT assay	[PMID: 30006164]
Platelet	IC₅₀	0.6 μM Compound: 2	Inhibition of collagen-induced platelet aggregation in human platelet suspension preincubated for 3 mins followed by collagen stimulation and measured after 6 mins by lumi-aggregometry Inhibition of collagen-induced platelet aggregation in human platelet suspension preincubated for 3 mins followed by collagen stimulation and measured after 6 mins by lumi-aggregometry	[PMID: 32463237]
RKO	IC₅₀	11.42 μM Compound: 35	Antitumor activity against human RKO cells assessed as reduction in cell viability incubated for 48 hrs by CCK8 assay Antitumor activity against human RKO cells assessed as reduction in cell viability incubated for 48 hrs by CCK8 assay	[PMID: 36332549]
RKO	IC₅₀	11.42 μM Compound: Honokiol	Antitumor activity against human RKO cells assessed as reduction in tumor growth incubated for 72 hrs by CCK8 assay Antitumor activity against human RKO cells assessed as reduction in tumor growth incubated for 72 hrs by CCK8 assay	[PMID: 38306267]
SW480	IC₅₀	15.14 μM Compound: 35	Antitumor activity against human SW480 cells assessed as reduction in cell viability incubated for 48 hrs by CCK8 assay Antitumor activity against human SW480 cells assessed as reduction in cell viability incubated for 48 hrs by CCK8 assay	[PMID: 36332549]
UACC-903	IC₅₀	5.1 μM Compound: Honokiol	Cytotoxicity against human UACC-903 cells after 72 hrs by MTS assay Cytotoxicity against human UACC-903 cells after 72 hrs by MTS assay	[PMID: 22533983]
UACC-903	IC₅₀	7.45 μM Compound: Honokiol	Cytotoxicity against human UACC-903 cells after 24 hrs by MTS assay Cytotoxicity against human UACC-903 cells after 24 hrs by MTS assay	[PMID: 22533983]
Vero	CC₅₀	22.5 μM Compound: 1, honokiol	Cytotoxicity against Vero cells Cytotoxicity against Vero cells	[PMID: 16722664]
Vero	CC₅₀	88.9 μM Compound: 18	Cytotoxicity against Vero E6 cells by MTT assay Cytotoxicity against Vero E6 cells by MTT assay	[PMID: 17663539]
Vero	EC₅₀	6.5 μM Compound: 18	Antiviral activity against SARS coronavirus in Vero E6 cells assessed as inhibition of viral replication by ELISA Antiviral activity against SARS coronavirus in Vero E6 cells assessed as inhibition of viral replication by ELISA	[PMID: 17663539]
Vero	IC₅₀	22.5 μM Compound: 2	Cytotoxicity against Vero cells Cytotoxicity against Vero cells	[PMID: 17587572]

In Vitro

Honokiol (0, 12.5, 25 and 50 μM) inhibits the growth of GBM cells and induces apoptosis, with IC₅₀ of appr against 30 μM DBTRG-05MG cell. Honokiol-induced apoptosis of GBM cells is associated with the downregulation of the Rb protein and cleavage of PARP and Bcl-x (S/L). Honokiol (50 μM) increases the level of autophagy markers in GBM cells^[1].
Honokiol has anticancer effect, and the IC₅₀ values with MDA-MB-231, MDA-MB-468, and MDA-MB-453 cell lines is 16.99 ± 1.28 μM, 15.94 ± 2.35 μM and 20.11 ±3.13 μM respectively. Honokiol (3, 10 μM) produces significant inhibition on the spheroid number and spheroid sizes in the clonogenic assay^[2].
Honokiol (0.1-1.0 μM) specifically inhibits washed human platelet aggregation stimulated by collagen, but not by other agonists. honokiol (0.6 and 1.0 μM) can concentration-dependently inhibit the collagen-induced ATP-release reaction in washed human platelets. Honokiol specifically inhibits platelet aggregation and the phosphorylation of Lyn, PLCγ2, and PKC stimulated with convulxin. Honokiol (5, 10 μM) significantly inhibits convulxin-stimulated MAPKs and Akt activation^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Honokiol-NM (40 mg/kg, p.o.) produces superior anticancer effects, and the PCNA, Cyclin D1 and cleaved caspase 3 expressions are 2.12, 1.92 and 1.68-fold significantly altered in this treated group^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

Chemical Information

CAS. Nr. 35354-74-6
Appearance Solid
Molecular Weight 266.33
Formel C₁₈H₁₈O₂
Color White to off-white
SMILES

OC1=C(CC=C)C=C(C2=CC(CC=C)=CC=C2O)C=C1
Synonyms

NSC 293100
Structure Classification
- Phenylpropanoids
- Lignans
Initial Source
Versand

Room temperature in continental US; may vary elsewhere.

Speicherung

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	1 year
	-20°C	6 months

Publications (69)

All In Vivo Efficacy StudyHistological Imaging/StainingCell Imaging/StainingWBIF

Sort by:

Journal Impact Factor

J Adv Res

Sodium-glucose exchanger 2 inhibitor canagliflozin promotes mitochondrial metabolism and alleviates salt-induced cardiac hypertrophy via preserving SIRT3 expression. [Abstract]

2024 May 12:S2090-1232(24)00173-5. PMID: 38744404
J Nanobiotechnology

Sirtuin-3 activation by honokiol attenuated anesthesia/surgery-induced cognitive impairment and neuronal ferroptosis via inhibiting mitochondrial GPX4 acetylation. [Abstract]

2025 Jun 4;23(1):414. PMID: 40462120
J Nanobiotechnology

Mesenchymal stem cell-derived extracellular vesicles alleviate autism by regulating microglial glucose metabolism reprogramming and neuroinflammation through PD-1/PD-L1 interaction. [Abstract]

2025 Mar 11;23(1):201. PMID: 40069859
Adv Sci (Weinh)

Skeletal Muscle HSF1 Alleviates Age-Associated Sarcopenia and Mitochondrial Function Decline via SIRT3-PGC1α Axis. [Abstract]

2025 Dec 16:e10368. PMID: 41400028
Adv Sci (Weinh)

Aldehyde Dehydrogenase 2 Lactylation Aggravates Mitochondrial Dysfunction by Disrupting PHB2 Mediated Mitophagy in Acute Kidney Injury. [Abstract]

2024 Dec 31:e2411943. PMID: 39737891

Honokiol purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2024 Dec 31:e2411943. [Abstract]

Honokiol (5 mg/kg) was injected intraperitoneally (i.p.) for three days before the injection of MA. Serum creatinine (Scr) and urea nitrogen (BUN) levels in MA‐AKI mice.

Honokiol purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2024 Dec 31:e2411943. [Abstract]

Images stained with hematoxylin and eosin (HE) after intraperitoneal injection of magnolol (5 mg/kg) three days prior to MA injection.

Honokiol purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2024 Dec 31:e2411943. [Abstract]

Three days before MA injection, magnolol (5 mg/kg) was injected intraperitoneally. Representative transmission electron microscopy (TEM) images of mitochondria in renal tubular epithelial cells of mice in each group.
Sci Adv

Genetically engineered chondrocyte-mimetic nanoplatform attenuates osteoarthritis by blocking IL-1β and restoring sirtuin-3. [Abstract]

2025 Jul 25;11(30):eadv4238. PMID: 40712009
Cell Death Dis

Honokiol suppresses the aberrant interactions between renal resident macrophages and tubular epithelial cells in lupus nephritis through the NLRP3/IL-33/ST2 axis. [Abstract]

2023 Mar 1;14(3):174. PMID: 36859530
Phytomedicine

Ginger-processed Magnoliae Officinalis Cortex ameliorates ovalbumin-induced asthma by alleviating inflammation via the gut-lung axis. [Abstract]

2025 Jun 11:145:156971. PMID: 40554292
Phytomedicine

Disruption of cholesterol homeostasis triggers NLRP3-cGAS-STING axis-dependent hepatic fibrosis and honokiol intervention effects. [Abstract]

2025 May 24:143:156904. PMID: 40449452
Phytomedicine

Fangchinoline suppresses nasopharyngeal carcinoma progression by inhibiting SQLE to regulate the PI3K/AKT pathway dysregulation. [Abstract]

2025 May:140:156484. PMID: 40090046
Phytomedicine

The role of daurisoline treatment in hepatocellular carcinoma: Inhibiting vasculogenic mimicry formation and enhancing sensitivity to sorafenib. [Abstract]

2021 Nov:92:153740. PMID: 34600176
Cell Death Discov

Thrombomodulin reduces α-synuclein generation and ameliorates neuropathology in a mouse model of Parkinson's disease. [Abstract]

2024 Apr 8;10(1):167. PMID: 38589400
J Transl Med

SIRT3 ameliorates diabetes-associated cognitive dysfunction via regulating mitochondria-associated ER membranes. [Abstract]

2023 Jul 22;21(1):494. PMID: 37481555
Chin Med J (Engl)

Honokiol attenuates mitochondrial fission and cell apoptosis by activating Sirt3 in intracerebral hemorrhage. [Abstract]

2023 Mar 20;136(6):719-731. PMID: 36805606
Int J Biol Macromol

A polysaccharide from Grifola frondosa fruit body induces HT-29 cells apoptosis by PI3K/AKT-MAPKs and NF-κB-pathway. [Abstract]

2020 Mar 15;147:79-88. PMID: 31923503

Honokiol purchased from MedChemExpress. Usage Cited in: Int J Biol Macromol. 2020 Mar 15;147:79-88. [Abstract]

Effect of GFP-A and Honokiol (activator of ERK1/2) (10 μmol/L) on the protein expression of NF-κB p65 in HT-29 cells. Cells were treated with 180 μg/mL GFP-A in the presence or absence of Honokiol for different durations of time. The expression of protein was analyzed by western blot. β-Actin was used as an equal loading control.
Int J Mol Med

Honokiol ameliorates pyroptosis in intestinal ischemia‑reperfusion injury by regulating the SIRT3‑mediated NLRP3 inflammasome. [Abstract]

2025 Jun;55(6):96. PMID: 40280115
Int J Mol Med

Honokiol antagonizes doxorubicin‑induced cardiomyocyte senescence by inhibiting TXNIP‑mediated NLRP3 inflammasome activation. [Abstract]

2020 Jan;45(1):186-194. PMID: 31746354
Mol Med

MiR-27a-3p promotes the osteogenic differentiation by activating CRY2/ERK1/2 axis. [Abstract]

2021 Apr 26;27(1):43. PMID: 33902432
Phytother Res

Honokiol Inhibits Stemness in Pancreatic Cancer via Downregulating c-Met Expression. [Abstract]

2026 Mar;40(3):873-886. PMID: 41518053
Free Radic Biol Med

The AMPK-PGC-1α-SIRT3 axis mediates mitochondrial metabolic dysfunction and neuronal senescence induced by Al(mal)3 exposure in HT22 hippocampal neuronal cells. [Abstract]

2026 Jun 9:254:78-90. PMID: 42263892
Free Radic Biol Med

SIRT3 promotes metabolic maturation of human iPSC-derived cardiomyocytes via OPA1-controlled mitochondrial dynamics. [Abstract]

2023 Feb 1:195:270-282. PMID: 36596388
Am J Chin Med

Honokiol Exhibits Anti-Tumor Effects in Breast Cancer by Modulating the miR-148a-5p-CYP1B1 Axis. [Abstract]

2024;52(6):1843-1861. PMID: 39347954
Aging Cell

JUNB-FBXO21-ERK axis promotes cartilage degeneration in osteoarthritis by inhibiting autophagy. [Abstract]

2021 Feb;20(2):e13306. PMID: 33450132
Neurosci Bull

Compound from Magnolia officinalis Ameliorates White Matter Injury by Promoting Oligodendrocyte Maturation in Chronic Cerebral Ischemia Models. [Abstract]

2023 Oct;39(10):1497-1511. PMID: 37291477
Cell Mol Life Sci

Mitochondrial oxidative stress inhibited Sirt3/Foxo3/PPARα pathway and aggravated copper and zinc co-deficiency-induced hepatic lipotoxicity in a fish model. [Abstract]

2025 Jun 5;82(1):226. PMID: 40471448
Cell Biosci

Remote ischemic preconditioning protects against spinal cord ischemia-reperfusion injury in mice by activating NMDAR/AMPK/PGC-1α/SIRT3 signaling. [Abstract]

2023 Mar 16;13(1):57. PMID: 36927808
Food Funct

Pine nut antioxidant peptides ameliorate the memory impairment in a scopolamine-induced mouse model via SIRT3-induced synaptic plasticity. [Abstract]

2021 Sep 7;12(17):8026-8036. PMID: 34269783
Cell Rep Methods

A fluorescent STING ligand sensor for high-throughput screening of compounds that can enhance tumor immunotherapy. [Abstract]

2025 Jul 21;5(7):101106. PMID: 40669456
Pharmaceuticals (Basel)

In Silico and In Vitro Profiling of Honokiol and Paclitaxel-Loaded PBM Nanoparticles for Targeted Breast Cancer Delivery. [Abstract]

2025 Nov 27;18(12):1814. PMID: 41471303
Pharmaceuticals (Basel)

Targeting Annexin A1 as a Druggable Player to Enhance the Anti-Tumor Role of Honokiol in Colon Cancer through Autophagic Pathway. [Abstract]

2023 Jan 1;16(1):70. PMID: 36678567
Eur J Pharmacol

A phycocyanin derived eicosapeptide attenuates lung fibrosis development. [Abstract]

2021 Oct 5;908:174356. PMID: 34280398
Int J Mol Sci

ERK1/2-CEBPB Axis-Regulated hBD1 Enhances Anti-Tuberculosis Capacity in Alveolar Type II Epithelial Cells. [Abstract]

2024 Feb 18;25(4):2408. PMID: 38397085
Int Immunopharmacol

Andrographolide attenuates Mycoplasma gallisepticum-induced inflammation and apoptosis by the JAK/PI3K/AKT signal pathway in the chicken lungs and primary alveolar type II epithelial cells. [Abstract]

2022 May 6;109:108819. PMID: 35533556
Int Immunopharmacol

SIRT3-AMPK signaling pathway as a protective target in endothelial dysfunction of early sepsis. [Abstract]

2022 May:106:108600. PMID: 35217431
Inflamm Bowel Dis

SIRT3 Activator Honokiol Inhibits Th17 Cell Differentiation and Alleviates Colitis. [Abstract]

2023 Dec 5;29(12):1929-1940. PMID: 37335900
Mucosal Immunol

Bilirubin represents a negative regulator of ILC2 in allergic airway inflammation. [Abstract]

2022 Feb;15(2):314-326. PMID: 34686839
Inflammation

Protective Effect of Sirtuin 3 on CLP-Induced Endothelial Dysfunction of Early Sepsis by Inhibiting NF-κB and NLRP3 Signaling Pathways. [Abstract]

2021 Oct;44(5):1782-1792. PMID: 33770326
J Integr Med

Honokiol protects against acute pancreatitis by activating SIRT3 to restore mitochondrial oxidative phosphorylation and alleviate hyperacetylation. [Abstract]

2026 Jan 28:S2095-4964(26)00008-7. PMID: 41656152
Chem Biol Interact

Honokiol improves cognitive impairment in APP/PS1 mice through activating mitophagy and mitochondrial unfolded protein response. [Abstract]

2022 Jan 5:351:109741. PMID: 34752757
AAPS PharmSciTech

Enhancement in the Transdermal and Localized Delivery of Honokiol Through Breast Tissue. [Abstract]

2018 Nov;19(8):3501-3511. PMID: 30259402
Sci Rep

SIRT3 suppresses renal cancer progression by regulating IDH2 acetylation. [Abstract]

2026 Feb 6;16(1):7619. PMID: 41651965
Neuropharmacology

Early-life sevoflurane exposure impairs fear memory by suppressing extracellular signal-regulated kinase signaling in the bed nucleus of stria terminalis GABAergic neurons. [Abstract]

2021 Jun 15:191:108584. PMID: 33933475
Aquaculture

2023 Apr 8,739553.
Fish Shellfish Immunol

Triclocarban evoked neutrophil extracellular trap formation in common carp (Cyprinus carpio L.) by modulating SIRT3-mediated ROS crosstalk with ERK1/2/p38 signaling. [Abstract]

2022 Oct:129:85-95. PMID: 36057428
Microbiol Spectr

Quantitative analysis of the lysine acetylome reveals the role of SIRT3-mediated HSP60 deacetylation in suppressing intracellular Mycobacterium tuberculosis survival. [Abstract]

2024 Jun 25:e0074924. PMID: 38916288
J Biol Chem

AKT Signaling Modulates Latent Viral Reservoir Viability in HIV-1-Infected Blood-Brain Barrier Pericytes. [Abstract]

2024 Jan;300(1):105526. PMID: 38043797
Microbiol Spectr

Honokiol Inhibits SARS-CoV-2 Replication in Cell Culture at a Post-Entry Step. [Abstract]

2023 Jun 15;11(3):e0327322. PMID: 37212560
Funct Integr Genomics

Honokiol attenuates renal fibrosis via SIRT3-Mediated regulation of Wnt/β-Catenin signaling. [Abstract]

2026 Feb 10;26(1):42. PMID: 41663594
Naunyn Schmiedebergs Arch Pharmacol

Honokiol inhibits cell migration and invasion by blocking EMT via Snail/Slug axis in endometriosis. [Abstract]

2025 Oct 22. PMID: 41123636
J Immunol

β-Arrestin 2 Regulates Inflammatory Responses against Mycobacterium tuberculosis Infection through ERK1/2 Signaling. [Abstract]

2021 Jun 1;206(11):2623-2637. PMID: 34001657
PLoS Negl Trop Dis

Identification of anti-flaviviral drugs with mosquitocidal and anti-Zika virus activity in Aedes aegypti. [Abstract]

2019 Aug 20;13(8):e0007681. PMID: 31430351
J Radiat Res Appl Sci

2026 Jun 11;19(3):102500.
Mol Biol Rep

Effects of honokiol protects against chronic kidney disease via BNIP3/NIX and FUNDC1-mediated mitophagy and AMPK pathways. [Abstract]

2023 Aug;50(8):6557-6568. PMID: 37338733
Food Chem Toxicol

Exposure to di-(2-ethylhexyl) phthalate reduces secretion of GDNF via interfering with estrogen pathway and downregulating ERK/c-fos signaling pathway in astrocytes. [Abstract]

2021 Dec:158:112592. PMID: 34624416
Exp Eye Res

SIRT3 mitigates dry eye disease through the activation of autophagy by deacetylation of FOXO1. [Abstract]

2025 May:254:110328. PMID: 40064414
Am J Hypertens

SIRT3/AMPK signaling pathway regulates lipid metabolism and improves vulnerability to atrial fibrillation in Dahl salt sensitive rats. [Abstract]

2024 Jul 18:hpae091. PMID: 39023012
Vet Microbiol

The Chinese medicine monomer Schisandrin C inhibits PRRSV infection by regulating the OGT-PI3K/AKT/mTOR signaling pathway. [Abstract]

2026 May:316:110992. PMID: 41865607
Dig Dis Sci

KISS-1, Mediated by Promoter Methylation, Suppresses Esophageal Squamous Cell Carcinoma Metastasis via MMP2/9/MAPK Axis. [Abstract]

2022 Oct;67(10):4780-4796. PMID: 34993679
J Nat Med

Xanthohumol attenuates TXNIP-mediated renal tubular injury in vitro and in vivo diabetic models. [Abstract]

2025 Mar;79(2):314-327. PMID: 39752106
Biochem Biophys Res Commun

Alleviation of fibrosis and oxidative stress in pressure overload-induced cardiac remodeling and heart failure via SIRT3 activation by colchicine. [Abstract]

2025 May 8:770:151957. PMID: 40373382
Biochem Biophys Res Commun

Honokiol improves endothelial function in type 2 diabetic rats via alleviating oxidative stress and insulin resistance. [Abstract]

2022 Apr 16:600:109-116. PMID: 35219098
Surg Oncol

BRCA1-associated protein induced proliferation and migration of gastric cancer cells through MAPK pathway. [Abstract]

2020 Dec;35:191-199. PMID: 32890957
Exp Anim

SIRT3 confers protection against acute pulmonary embolism by anti-inflammation, anti-oxidative stress, anti-apoptosis: participation of AMPK/mTOR pathway. [Abstract]

2023 Aug 7;72(3):346-355. PMID: 36858596

Honokiol purchased from MedChemExpress. Usage Cited in: Exp Anim. 2023 Aug 7;72(3):346-355. [Abstract]

IF staining assays demonstrates that Honokiol (5 mg/kg; i.p.; single) elevates the expression of SIRT3 in the lung tissues of APE (acute pulmonary embolism) rats.
J Obstet Gynaecol Res

Honokiol induces ferroptosis in ovarian cancer cells through the regulation of YAP by OTUB2. [Abstract]

2024 May;50(5):864-872. PMID: 38480480
Heliyon

LncRNA GAS5 downregulates NLRP3 inflammasome activation-mediated pyroptosis in sepsis-induced myocardial injury by targeting SIRT3/AMPKα. [Abstract]

2023 Nov 28;9(12):e22939. PMID: 38076153
bioRxiv

2023 Jul 9.
SSRN

22 Apr 2022.
Research Square Preprint

2020 Oct.
Biomed Pharmacother

Cytological effects of honokiol treatment and its potential mechanism of action in non-small cell lung cancer. [Abstract]

2019 Sep:117:109058. PMID: 31176168

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : ≥ 50 mg/mL (187.74 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

* "≥" means soluble, but saturation unknown.

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

3.7547 mL

18.7737 mL

37.5474 mL

5 mM

0.7509 mL

3.7547 mL

7.5095 mL

10 mM

0.3755 mL

1.8774 mL

3.7547 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (9.39 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.5 mg/mL (9.39 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (9.39 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

Working Solution

For the following dissolution methods, please prepare the working solution directly:

It is recommended to prepare fresh solutions and use them promptly within a short period of time.

The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: Corn Oil

Solubility: 16.67 mg/mL (62.59 mM); Clear solution; Need ultrasonic

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Protokoll

Cell Assay^[2]

In cytotoxicity assays, 10,000 cells/well are added to 96 wells plates and incubated overnight, thereafter cells are treated with different concentrations of Honokiol dissolved in dimethylsulphoxide (DMSO). Since Honokiol is not soluble in aqueous solvents, for in vitro studies Honokiol is dissolved in DMSO. To study the possible effect of DMSO on cells, solvent (DMSO) control is used at highest concentration of <0.1%. After 72 h treatment, cells are fixed and cell viability is measured by crystal violet staining (0.05%).

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Administration^[2]

For anticancer in vivo studies, the MDA-MB-231 cells (2 million) are injected into mammary fat tissue. Two weeks after the tumor cell injections, palpable tumors are observed in mammary tissues, which is an indication of tumor formation. Then drug treatment either in free form or in nanomicellar forms is given orally at the dose of 40 and 80 mg/kg daily. The drug treatment is continued for 4 weeks, and the tumor volumes and body weights are recorded weekly. After 4 weeks of treatment, animals are sacrificed; final tumor volumes and weights are measured. These tumors are used for western blot and immunohistochemical analysis. For western blot experiments, tumor tissues are stored at −80°C till the analysis is done. For IHC, tumors are fixed in formal saline.

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (283 KB)
SDS (620 KB)
- English - EN (620 KB)
- Français - FR (620 KB)
- Deutsch - DE (620 KB)
- Norwegian - NO (620 KB)
- Español - ES (620 KB)
- Swedish - SV (620 KB)
- Italian - IT (620 KB)
- Korean - KR (620 KB)
- Portuguese - PT (620 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Chang KH, et al. Honokiol-induced apoptosis and autophagy in glioblastoma multiforme cells. Oncol Lett. 2013 Nov;6(5):1435-1438. [Content Brief]

[2]. Godugu C, et al. Honokiol nanomicellar formulation produced increased oral bioavailability and anticancer effects in triple negative breast cancer (TNBC). Colloids Surf B Biointerfaces. 2017 Jan 23;153:208-219 [Content Brief]

[3]. Lee TY, et al. Honokiol as a specific collagen receptor glycoprotein VI antagonist on human platelets: Functional ex vivo and in vivo studies. Sci Rep. 2017 Jan 5;7:40002 [Content Brief]

[4]. Zhai H, et al. Honokiol-induced neurite outgrowth promotion depends on activation of extracellular signal-regulated kinases (ERK1/2). Eur J Pharmacol. 2005 Jun 1;516(2):112-7. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	3.7547 mL	18.7737 mL	37.5474 mL	93.8685 mL
	5 mM	0.7509 mL	3.7547 mL	7.5095 mL	18.7737 mL
	10 mM	0.3755 mL	1.8774 mL	3.7547 mL	9.3869 mL
	15 mM	0.2503 mL	1.2516 mL	2.5032 mL	6.2579 mL
	20 mM	0.1877 mL	0.9387 mL	1.8774 mL	4.6934 mL
	25 mM	0.1502 mL	0.7509 mL	1.5019 mL	3.7547 mL
	30 mM	0.1252 mL	0.6258 mL	1.2516 mL	3.1290 mL
	40 mM	0.0939 mL	0.4693 mL	0.9387 mL	2.3467 mL
	50 mM	0.0751 mL	0.3755 mL	0.7509 mL	1.8774 mL
	60 mM	0.0626 mL	0.3129 mL	0.6258 mL	1.5645 mL
	80 mM	0.0469 mL	0.2347 mL	0.4693 mL	1.1734 mL
	100 mM	0.0375 mL	0.1877 mL	0.3755 mL	0.9387 mL

Keywords

Honokiol

69 Cited Publications

100 mg Angebot einholen

Subscribe to the

MedChemExpress

Newsletter

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

Honokiol

Anti-Infection Compound Library

Immunology/Inflammation Compound Library

Kinase Inhibitor Library

MAPK Compound Library

PI3K/Akt/mTOR Compound Library

Stem Cell Signaling Compound Library

Natural Product Library

Anti-Cancer Compound Library

Clinical Compound Library

Antiviral Compound Library

CNS-Penetrant Compound Library

Autophagy Compound Library

Anti-Aging Compound Library

Drug Repurposing Compound Library

Differentiation Inducing Compound Library

Oxygen Sensing Compound Library

Medicine Food Homology Compound Library

Glycolysis Compound Library

Cytoskeleton Compound Library

Glutamine Metabolism Compound Library

Traditional Chinese Medicine Active Compound Library

FDA Approved & Pharmacopeial Drug Library

Neuroprotective Compound Library

Anti-Hepatitis C Virus Compound Library

Anti-Breast Cancer Compound Library

Anti-Lung Cancer Compound Library

Anti-Pancreatic Cancer Compound Library

Anti-Blood Cancer Compound Library

Anti-Cancer Metabolism Compound Library

Anti-Obesity Compound Library

Angiogenesis-Related Compound Library

Glucose Metabolism Compound Library

Anti-Liver Cancer Compound Library

Anti-Colorectal Cancer Compound Library

Anti-Cancer Natural Product Library

Antidepressant Compound Library

Antiviral Traditional Chinese Medicine Active Compound Library

Anti-inflammatory Traditional Chinese Medicine Active Compound Library

Plant-Sourced Natural Product Library

Human Metabolite Library

Anti-Prostate Cancer Compound Library

Anti-Pulmonary Fibrosis Compound Library

Osteogenesis Compound Library

Cancer Stem Cells Compound Library

Pain-Related Compound Library

Cell Death Library

Serine/Threonine Kinase Inhibitor Library

Anti-Hematopathy Compound Library

Anti-Ovarian Cancer Compound Library

Multi-Target Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Natural Product Library Plus

Drug Repurposing Compound Library Plus

Clinical Compound Library Plus

Natural Product and Natural Product-Like Compound Library

Bioactive Compound Library

Anti-Gastric Cancer Compound Library

Anti-Fibrosis Compound Library

Tibetan Medicine Compound Library

Protein Kinase Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

RO5 Drug-like Natural Product Library

Cell Proliferation Compound Library

High-Throughput Bioactive Compound Library

High-Throughput Natural Product Library

Ancient Chinese Classical Formulas Traditional Chinese Medicine Active Compound Library

Mass Spectrometry Human Metabolite Library

Cosmetic Ingredient Compound Library

Diarrhea-Related Traditional Chinese Medicine Active Compound Library

Posttranslational Modification Library

Mongolian Medicine Compound Library

RNA Binding Bioactive Compound Library

Lactylation Compound Library

Mass Spectrometry Natural Product Library

Publications Citing Use of MedChemExpress (MCE) Honokiol

Alle Akt Isoform-spezifische Produkte anzeigen

Alle ERK Isoform-spezifische Produkte anzeigen

Biologische Aktivität